By Professor David Goldstein

Conference Papers

Tebbutt N; Gebski V; Strickland A; Gibbs D; Walpole E; Ganju V; Goldstein D; Munro S; Harrod M; Van Hazel G, 2006, 'Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, GA, Atlanta, pp. 194S - 194S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006

Stockler MR; Heritier S; Nowak AK; Goldstein D; Turner J; Jeord M; Glasgow A; Abdi E; Beale PJ; Carter C, 2006, 'The time taken to complete quality of life questionnaires in an advanced cancer trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, GA, Atlanta, pp. 491S - 491S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006

Joshi SB; Vonlaufen A; Xu Z; Daniel B; Qu CF; Kumar RK; Pirola RC; Wilson JS; Goldstein D; Apte MV, 2006, 'Pancreatic stellate cells stimulate pancreatic cancer growth and metastasis: Findings of a novel orthotopic model of pancreatic cancer', in Pancreas, Lippincott Williams & Wilkins, Philadelphia, PA, USA, -

Joshi SB; Qu CF; Phillips PA; Pirola RC; Wilson JS; Goldstein D; Apte MV, 2005, 'Epithelial-stromal interactions in pancreatic cancer: do pancreatic cancer cells actively recruit host stromal cells for their own benefit?', in The Peter McCallum Institute (ed.), 6th Peter MacCallum Cancer Symposium, Molecular and Cell Biology of Cancer, Melbourne, pp. 21 - 21, presented at 6th Peter MacCallum Cancer Symposium, Molecular and Cell Biology of Cancer, Melbourne, 14 November 2005 - 16 November 2005

Au HJ; Goldstein D; Ding K; Parulekar W; Gallinger S; Moore M, 2005, 'DOES EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR (EGFRI) SKIN TOXICITY AFFECT QOL? RESULTS FROM A NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP (NCIC-CTG) RCT', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 2135 - 2135, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000520235700429&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goldstein D; Spry N; Van Hazel GA; Underhill CR; Kotasek D; Harvey JE; Links MJ; Shapiro J; Iacopetta BJ, 2005, 'Combined modality therapy for pancreatic carcinoma: An australian pancreatic cancer group study of the addition of gemcitabine (G) to concurrent infusional 5-fluorouracil (CI5FI)and 3D conformal radiotherapy (RT)-final outcomesAbstract No: 4101', in Bhave AB (ed.), Journal of Clinical Oncology, Jitendar P Vij, Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India, pp. 203s - 203s, presented at 42nd Annual Meeting of the Amercian Society of Clinical Oncology, Atlanta, Georgia USA, 02 June 2005 - 06 June 2005

Gwo-Tzer H; Soranzo N; Tenesa A; Goldstein D; Satsangi J, 2005, 'Specific haplotypic variations of the multidrug resistance 1 (ABCB1/MDR1) gene are associated with susceptibility or resistance to ulcerative colitis', in GASTROENTEROLOGY, W B SAUNDERS CO, IL, Chicago, pp. A441 - A442, presented at Annual Meeting of the American-Gastroenterological-Association/Digestive-Disease-Week, IL, Chicago, 14 May 2005 - 19 May 2005

Mitchell P; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; Clarke S; White S, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, pp. 266S - 266S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326601475&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goldstein D; van Hazel G; Pavlakis N; Olver I, 2005, 'Selective internal radiation therapy (SIRT) plus systemic chemotherapy with irinotecan. A phase I dose escalation study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, pp. 296S - 296S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005

Goldstein D; Van Hazel GA; Underhill CR; Kotasek D; Harvey JE; Links MR; Shapiro J; Iacopetta BJ; Spry N; Lilly E, 2004, '', in Journal of Clinical Oncology, Jitendar P Vij, Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India

Evans VE; Vockler C; Magnay J; Friedlander N; Lewis CR; Goldstein D; Walsh BR; Holden BA; Willcox MD, 2000, 'Lacryglobin in human tears, a potential marker for cancer metastasis', in Australian and New Zealand Journal of Ophthalmology, Blackwell Science Asia, South Carlton, Australia, pp. 36 - 36, presented at Australasian Ophthalmic and Visual Sciences Meeting 2000, Sydney

Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J, 1997, 'A randomized study of paclitaxel versus cyclophosphamide/methotrexate/- fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results', in Seminars in Oncology, pp. S17 - S17

Newell M; Milliken S; Chipman M; Cebon J; Lewis C; Goldstein D; Cooper DA, 1997, 'DOX-SL (stealth liposomal doxorubicin HCL) maintenance therapy after response in AIDS-related Kaposi's sarcoma', in JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, LIPPINCOTT-RAVEN PUBL, pp. 15 - 15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WU25100049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Padiglione AA; Goldstein D; Law MG; Kaldor JM; Mijch AM; Hoy JF, 1997, 'Prognosis in Kaposi's sarcoma as an initial and later AIDS associated illness', in JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, LIPPINCOTT-RAVEN PUBL, pp. 16 - 16, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WU25100051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goldstein D; Milliken ST; Chipman M; Lebon J; Lewis CR; Cooper DA, 1997, 'Dox-SL maintenance therapy after response in AIDS-related Kaposis Sarcoma.', in J. AIDS and Human Retrovirology, presented at J. AIDS and Human Retrovirology

Goldstein D; Davis A; Milliken ST, 1997, 'Long term follow-up of CEOP in the treatment of HIV related NHL.', in J. AIDS and Human Retrovirology, presented at J. AIDS and Human Retrovirology

Goldstein D; Padigliene A; Law MG; Kaldor JM; Mijch AM; Hoy JF, 1997, 'Prognosis of Kaposi`s sarcoma as an initial and later AIDS associated illness.', in J. AIDS and Human Retrovirology, presented at J. AIDS and Human Retrovirology

Newell M; Milliken S; Chipman M; Cebon J; Lewis C; Goldstein D; Cooper DA, 1996, 'DOX-SL (stealth liposomal doxorubicin HCl) maintenance therapy after response in AIDS-related Kaposi's sarcoma.', in AIDS, LIPPINCOTT WILLIAMS & WILKINS, pp. P133 - P133, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VU96300195&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goldstein D; Cooper DA, 1993, 'Current status of clinical trials in HIV disease in Australia', in Journal of Acquired Immune Deficiency Syndromes, pp. S68 - S71

GOLDSTEIN D; SIELAFF K; STORER BE; WITT PL; BROWN RR; DATTA SP; SMALLEY RV; BORDEN EC, 1989, 'EFFECT OF DOSE ON BIOLOGICAL RESPONSE MODIFICATION BY INTERFERON-BETA-SER', in JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, LIPPINCOTT-RAVEN PUBL, pp. 327 - 328

WITT PL; GOLDSTEIN D; CORMIER E; BORDEN EC, 1989, 'EFFECTS OF INTERFERON AND ESTROGEN ON THE CYTOSKELETON OF HUMAN-BREAST TUMOR-CELL LINES', in JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, LIPPINCOTT-RAVEN PUBL, pp. 322 - 322

GOLDSTEIN D; SIELAFF K; STORER B; SMALLEY RV; BORDEN EC; WITT P; BROWN R; DATTA S, 1988, 'EFFECT OF ROUTE ON BIOLOGICAL RESPONSE MODIFICATION BY INTERFERON BETA-SER', in PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, pp. 184 - 184

Ko A; Reni M; Riess H; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Tabernero J; Van Cutsem E; Philip P; Goldstein D; Berlin JD; Ferrara S; Li M; Lu B; Romano A; Marks H; Biankin A; Tempero MA, 'APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1464 - 1464

Conference Proceedings (Editor of)

Yang JL; Qu XJ; Russell PJ; Goldstein D, (eds.), 2003, 'Cytokines, Signalling and Diseases 2003', Cairns, Qld, presented at Cytokines, Signalling and Diseases 2003, Cairns, Qld, 26 October 2003 - 30 October 2003

Ngan SY; Fisher R; Burmeister B; Rischin D; Mackay J; Kneebone A; McKendrick J; Goldstein D; McClure B; Joon DL; Joseph D, (eds.), 2002, 'American Society of Clinical Oncology', Orlando, Florida, USA, presented at American Society of Clinical Oncology, Orlando, Florida, USA, 18 May 2002 - 22 May 2002

Conference Posters

Reni M; Riess H; O'Reilly EM; Park JO; Hatoum H; Saez BL; Salminen T; Oettle H; Lopez R; Dowden SD; Karthaus M; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Tempero MA, 2020, 'Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.', Vol. 38, pp. 4515 - 4515, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4515

Iioanni L; maharaj A; loughan J; zalcberg J; earnest A; Goldstein D; Kench J; Merrett N; christophi C; croagh D; pilgrim C; burmeister E; white K; neale R; green S; evans S, 2019, 'Prognostic models to predict survival in patients with pancreatic cancer: A systematic review', Bangkok, presented at ASM RACS, Bangkok, 06 May 2019 - 10 May 2019

Wang X; crowe PC; goldstein DG; Yang JY, 2017, 'In vitro and in vivo effect of targeting CDK4/6 and mTOR singly or together in sarcoma cell lines', Adelaide, Australia, presented at 2017 Annual Sarcoma Conference, Adelaide, Australia, 13 October 2017 - 14 October 2017

Wang X; Crowe PC; Goldstein DG; Yang JY, 2017, 'Anti-prolifeative effect of targeting CDK4/6 and mTOR alone or in combination in sarcoma cell lines', Florence, Italy, presented at EACR-AACR-SIC: The Challenges of optimising immuno and targeted therapies: from cancer biology to the clinic, Florence, Italy, 24 June 2017 - 27 June 2017

Wang X; Crowe PJ; Goldstein D; Yang JL, 2015, 'Overcoming resistance of targeted EGFR/panHER monotherapy by inhibition of STAT3 escape pathway in sarcoma', Lorne, Victoria, Australia, Vol. 7, pp. 21496 - 21509, presented at 27th Lorne Cancer Conference 2015, Lorne, Victoria, Australia, 12 February 2015 - 14 February 2015, http://dx.doi.org/10.18632/oncotarget.7452

Lim HJ; Wang X; Goldstein ; Crowe , 2015, 'Targeting the PI3K/PTEN/AKT/mTOR pathway in sarcoma cell lines', Lorne, Victoria, Australia, presented at 27th Lorne Cancer Conference 2015, Lorne, Victoria, Australia, 12 February 2015 - 14 February 2015

Wang X; Goldstein ; Crowe ; Yang , 2014, 'Effect and mechanism of PF299804 alone and in combination with STAT3 inhibitor in human sarcoma cell lines', San Diego, CA, PA, presented at The 105th Annual Meeting of the American Association for Cancer Research 2014, San Diego, CA, PA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-172

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'Mechanisms of gefitinib alone and in combination therapy in soft tissue sarcoma cell lines', Boston, MA, US, presented at Molecular Targets and Cancer Therapeutics 2013, Boston, MA, US, 19 October 2013 - 23 October 2013

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'STAT3 inhibitor S3I-201 suppresses human osteosarcoma cell growth', Lorne, Victoria, Australia, presented at 25th Lorne Cancer Conference 2013, Lorne, Victoria, Australia, 14 February 2013 - 16 February 2013

Wang X; Goldstein D; Crowe P; Yang J, 2012, 'Treatment of soft tissue sarcoma cells by EGFR and/or STAT3 inhibitors', presented at The 103rd Annual Meeting of AACR 2012, 31 March 2012 - 04 April 2012

Wang X; Goldstein D; Crowe P; Yang J, 2012, 'STAT3-targeted therapy on human soft tissue sarcomas', Lorne, Victoria, Australia, presented at 24th Lorne Cancer Conference 2012, Lorne, Victoria, Australia, 09 February 2012 - 11 February 2012

Conference Presentations

maharaja A; evans S; neale R; Goldstein D; Merrett N; zalcberg J, 2018, 'Patient-Reported Outcome Measures (PROMs) in Pancreatic Cancer: A Systematic Review', presented at ANZGOSA/ANZHPBA conjoint meeting, Weelington New Zealand, 08 October 2018 - 09 October 2018

Meiser B; Zilliacus E; Wong T; Girgis A; Butow P; Hale S; Kissane D; Perry A; Aranda S; Tomkins S; Hodges J; Norris C; Shaw T; Tebble H; Woodland L; Kaur R; Goldstein D, 2015, 'Communication skills training for oncology health care professionals working with culturally and linguistically diverse patients'

Burmeister E; Jordan S; O'Connell D; Vanessa B; David G; Helen G; Monka J; Neil M; David W; Rachel N, 2015, 'Using a Delphi process to determine optimal care for patients with pancreatic cancer', http://dx.doi.org/10.1016/j.pan.2015.05.308

Wang X; Goldstein D; Crowe P; Yang J-L, 2014, 'Effect and mechanism of PF299804 alone and in combination with STAT3 inhibitor in human sarcoma cell lines', presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-1723

Girgis A; Webber K; Bennetts BH; Bonaventura A; Boyle F; Koh E; Friedlander M; Segelov E; Goldstein D, 2012, '"This follow-up care would meet my needs, but I would still worry that problems with my health would not be found": A cross-sectional survey of adult cancer survivors', presented at COSA 39th Annual Scientific Meeting

Conference Abstracts

Joda M; Li T; Timmins H; Goldstein D; Park S, 2024, 'IDENTIFICATION OF AXONAL DEGENERATION IN PACLITAXEL-TREATED PATIENTS UTILISING NEUROPHYSIOLOGICAL AND BLOOD BASED BIOMARKERS', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, CANADA, Montreal, Vol. 29, pp. S177 - S177, presented at Annual Meeting of the Peripheral-Nerve-Society (PNS), CANADA, Montreal, 22 June 2024 - 25 June 2024

Li T; Timmins H; Mahfouz F; Trinh T; Mizrahi D; Horvath L; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan M; Rutherford C; Goldstein D; Park S, 2024, 'IDENTIFYING THE OPTIMAL OUTCOME MEASURE TO ASSESS CHEMOTHERAPY-INDUCED PERIPHERAL NEUROTOXICITY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, CANADA, Montreal, Vol. 29, pp. S178 - S178, presented at Annual Meeting of the Peripheral-Nerve-Society (PNS), CANADA, Montreal, 22 June 2024 - 25 June 2024

Pitiyarachchi O; Lin FP; Spooner A; Sharbeen G; Barker HP; Thornton K; Collignon E; Ballinger ML; Thomas DM; Magenau A; Porazinski S; Raina A; Sjoquist KM; Chantrill LA; Gebski V; Sowmya A; Timpson P; Pajic M; Goldstein D; Phillips PA, 2024, '1513P Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S925 - S925, http://dx.doi.org/10.1016/j.annonc.2024.08.1576

Kong BY; Lin FP-Y; Espinoza D; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Selva-Nayagam S; Charakidis M; Cuff K; Sebastian L; Lee CK; Chinchen S; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S505 - S505, http://dx.doi.org/10.1016/j.annonc.2024.08.703

Netto KG; Chiang S; Kokkinos J; Haghighi KS; Raina A; Pitiyarachchi O; Youkhana J; Truong Q; Wenholz D; Li X; Laczka O; Kumar N; Wilkinson J; Goldstein D; Sharbeen G; Phillips PA, 2023, 'CRO67 has therapeutic potential against pancreatic tumor cells and cancer associated fibroblasts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-B062

Hosen SMZ; Xu Z; Mekapogu AR; Perera C; Goldstein D; Pirola R; Wilson J; Buckley BJ; Ranson M; Apte M, 2022, 'Targeted urokinase plasminogen activator inhibition combined with chemotherapy halts primary tumor growth and eliminates metastasis in advanced pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 37, pp. 36 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852585700069&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', in Medicine & Science in Sports & Exercise, LIPPINCOTT WILLIAMS & WILKINS, San Diego, California, Vol. 54, pp. 322 - 322, presented at ACSM 2022 Annual Meeting & World Congresses, San Diego, California, 31 May 2022 - 04 June 2022, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b

Back to profile page